PMGC Holdings Inc. (ELAB): Cost of Revenue

Annual figures by period end, from SEC filings.

$404.8K

Year ended 2025-12-31

+8.3%

3-year compound annual growth

2022-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$404.8K	n/a	2026-03-30, From 2025-01-01
No annual figure between 2023-12-31 and 2025-12-31.
2023-12-31	$578.0K	+81.2%	2024-03-29, From 2023-01-01
2022-12-31	$319.0K	n/a	2024-03-29, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
PMGC Holdings Inc. (ELAB)	2025-12-31	$404.8K	n/a
Silence Therapeutics plc (SLN)	2025-12-31	$215.0K	-98.2%
BioXcel Therapeutics, Inc. (BTAIQ)	2025-12-31	$164.0K	-92.3%
Polomar Health Services, Inc. (PMHS)	2025-12-31	$188.1K	+573.8%
Quantum Cyber N.V. (QUCY)	2025-12-31	$147.3K	-53.8%
Lexaria Bioscience Corp. (LEXX)	2025-08-31	$2.7K	-43.6%
Scienture Holdings, Inc. (SCNX)	2025-12-31	$100.1K	-23.4%
Onconetix, Inc. (ONCO)	2025-12-31	$182.5K	-87.6%
America Great Health (AAGH)	2025-06-30	$52.6K	-57.9%

Compare ELAB, SLN, BTAIQ, PMHS side by side · Screen every company in Pharmaceutical Preparations ↗